EGFR and lung carcinoma: In total, 66 samples obtained from 30 patients with lung cancer pre-TKI or post-TKI therapy (erlotinib (EGFR), osimertinib (EGFR) and crizotinib (ALK) being the most frequent targeted therapies) were analyzed (Supplementary Table 2a).